Answers are grounded in this paper and cite their sources.
Preclinical model demonstrates distinct IL-36 receptor expression patterns in barrier tissues, suggesting new avenues for targeted autoimmune therapies.
IL-36 cytokines are emerging as beneficial in immunity against pathogens and cancers but can also be detrimental when dysregulated in autoimmune and autoinflammatory conditions. Interest in targeting IL-36 activity for therapeutic purposes is rapidly growing, yet many unknowns about the functions of these cytokines remain. Thus, the availability of robust research tools is essential for both fundamental basic science and pre-clinical studies to fully access outcomes of any manipulation of the system. For this purpose, a floxed
No takes yet. Share an insight, caveat, or question.
Tongmuang et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: